Literature DB >> 9151856

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.

J F Dedieu1, E Vigne, C Torrent, C Jullien, I Mahfouz, J M Caillaud, N Aubailly, C Orsini, J M Guillaume, P Opolon, P Delaere, M Perricaudet, P Yeh.   

Abstract

We have compared the in vitro and in vivo behaviors of a set of isogenic E1- and E1/E4-defective adenoviruses expressing the lacZ gene of Escherichia coli from the Rous sarcoma virus long terminal repeat. Infection of tumor-derived established cell lines of human origin with the doubly defective adenoviruses resulted in (i) a lower replication of the viral backbone that correlated with reduced levels of E2A-specific RNA and protein, (ii) a significant shutoff of late gene and protein expression, and (iii) no apparent virus-induced cytotoxicity. Independently of the extent of the deletion, the additional inactivation of E4 from the viral backbone therefore drastically disabled the virus in vitro, with no apparent effect on transgene expression. A lacZ-transgenic model was used to compare the different recombinant adenoviruses in the livers of C57BL/6 mice. The immune response to the virally encoded beta-galactosidase was minimal in this model, as infusion of the E1-defective adenovirus resulted in a time course of transgene expression that mimicked that in immunodeficient (nu/nu) mice, with very little inflammation and necrosis in the liver. Administration of a doubly defective adenovirus to the transgenic animals led to long-term extrachromosomal persistence of viral DNA in the liver, with no detectable methylation of CpG dinucleotides. However, transient transgene expression was observed independently of the extent of the E4 deletion, suggesting that the choice of the promoter may be critical to maintain transgene expression from these attenuated adenovirus vectors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151856      PMCID: PMC191684     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

2.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1.

Authors:  R J O'Connor; P Hearing
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenoviral E4 19 kDa protein.

Authors:  R Fagan; K J Flint; N Jones
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

5.  Stimulation of the adenovirus major late promoter in vitro by transcription factor USF is enhanced by the adenovirus DNA binding protein.

Authors:  D C Zijderveld; F d'Adda di Fagagna; M Giacca; H T Timmers; P C van der Vliet
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Dexamethasone enhancement of gene expression after direct hepatic DNA injection.

Authors:  R W Malone; M A Hickman; K Lehmann-Bruinsma; T R Sih; R Walzem; D M Carlson; J S Powell
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

7.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.

Authors:  G P Gao; Y Yang; J M Wilson
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

8.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

10.  DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein.

Authors:  L R Bandara; E W Lam; T S Sørensen; M Zamanian; R Girling; N B La Thangue
Journal:  EMBO J       Date:  1994-07-01       Impact factor: 11.598

View more
  25 in total

1.  E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors.

Authors:  D Armentano; M P Smith; C C Sookdeo; J Zabner; M A Perricone; J A St George; S C Wadsworth; R J Gregory
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Optimization of the helper-dependent adenovirus system for production and potency in vivo.

Authors:  V Sandig; R Youil; A J Bett; L L Franlin; M Oshima; D Maione; F Wang; M L Metzker; R Savino; C T Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes.

Authors:  J M Kaplan; D Armentano; A Scaria; L A Woodworth; S E Pennington; S C Wadsworth; A E Smith; R J Gregory
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

Review 4.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

5.  Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.

Authors:  D E Brough; C Hsu; V A Kulesa; G M Lee; L J Cantolupo; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

6.  Replication-defective vector based on a chimpanzee adenovirus.

Authors:  S F Farina; G P Gao; Z Q Xiang; J J Rux; R M Burnett; M R Alvira; J Marsh; H C Ertl; J M Wilson
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

7.  Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.

Authors:  V Molinier-Frenkel; H Gahery-Segard; M Mehtali; C Le Boulaire; S Ribault; P Boulanger; T Tursz; J G Guillet; F Farace
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs.

Authors:  N Chirmule; J V Hughes; G P Gao; S E Raper; J M Wilson
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears.

Authors:  J W Moorhead; G H Clayton; R L Smith; J Schaack
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.